Welcome to The Pharmacogenomics Journal

The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications. Publishing six times a year, the journal aims to provide the highest caliber of coverage concerning the effects of genetic variability on drug toxicity and efficacy, the characterization of polymorphisms relevant to drug action, and the identification of novel genomic targets for drug development.


Ranked in the top 10% of Pharmacology & Pharmacy titles*, with an impact factor that continues to rise, and a commitment to speedy online publication, Editor-in-Chief, Julio Licinio, invites you to join our mission of delivering compelling research to the scientific community by submitting your original research to The Pharmacogenomics Journal.


Volume 17, No 4
July 2017

ISSN: 1470-269X
EISSN: 1473-1150

2016 Impact Factor 3.815*
51/256 Pharmacology & Pharmacy
46/166 Genetics & Heredity

Editor:
Julio Licinio, MD

*2016 Journal Citation Reports® Science Edition (Clarivate Analytics, 2017)

NEWS

The authors of a recent paper present RH panels as a cost-effective and efficient tool to identify mammalian drug targets at single-gene resolution. Using a human RH panel, the authors identified an important gene for the action of antitubulin drugs that had been overlooked by other strategies.

The results of a recent study published in The Pharmacogenomics Journal provide insight into both unique and shared clinical effects of leukotriene modifiers (LTMs) in treatment of asthma, and represent a potential mechanism for the responsiveness to leukotriene antagonists in asthma patients.

Visit Nature Publishing Group's open access funding page for information about research funders and institutions that provide funding for open access. NPG also offers an APC support service to make it easier for NPG authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

TOP TEN MOST VIEWED PAPERS


The Top Ten charts the articles that have been downloaded most often over the previous 30 days, in HTML and PDF format, from the The Pharmacogenomics Journal website. The chart does not rank the quality, scientific significance or citation impact of the content. However, it may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them.


August 2017

  1. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

    M Ingelman-Sundberg

    doi:10.1038/sj.tpj.6500285

    Abstract | Full Text | PDF

  2. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

    M Verbelen, M E Weale & C M Lewis

    doi:10.1038/tpj.2017.21

    Abstract | Full Text | PDF

  3. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes

    C Guillemette

    doi:10.1038/sj.tpj.6500171

    Abstract | Full Text | PDF

  4. More than 25 years of genetic studies of clozapine-induced agranulocytosis

    S A J de With, S L Pulit, W G Staal, R S Kahn & R A Ophoff

    doi:10.1038/tpj.2017.6

    Abstract | Full Text | PDF

  5. Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study

    S Mahurkar, M Moldovan, V Suppiah, M Sorosina, F Clarelli, G Liberatore, S Malhotra, X Montalban, A Antigüedad, M Krupa, V G Jokubaitis, F C McKay, P N Gatt, M J Fabis-Pedrini, V Martinelli, G Comi, J Lechner-Scott, A G Kermode, M Slee, B V Taylor, K Vandenbroeck, M Comabella, F M Boneschi, C King & The Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene)

    doi:10.1038/tpj.2016.20

    Abstract | Full Text | PDF

  6. Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput

    X Chen & P F Sullivan

    doi:10.1038/sj.tpj.6500167

    Abstract | Full Text | PDF

  7. The clinical role of genetic polymorphisms in drug-metabolizing enzymes

    D Tomalik-Scharte, A Lazar, U Fuhr & J Kirchheiner

    doi:10.1038/sj.tpj.6500462

    Abstract | Full Text | PDF

  8. Prevalence and implications of cytochrome P450 substrates in Massachusetts hospital discharges

    T H McCoy, V M Castro, A Cagan, A M Roberson & R H Perlis

    doi:10.1038/tpj.2016.24

    Abstract | Full Text | PDF

  9. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies

    E C M Tonk, D Gurwitz, A-H Maitland-van der Zee & A C J W Janssens

    doi:10.1038/tpj.2016.34

    Abstract | Full Text | PDF

  10. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis

    N D Loft, L Skov, L Iversen, R Gniadecki, T N Dam, I Brandslund, H J Hoffmann, M R Andersen, R B Dessau, A C Bergmann, N M Andersen, P S Andersen, S Bank, U Vogel & V Andersen

    doi:10.1038/tpj.2017.31

    Abstract | Full Text | PDF

Extra navigation

16 August 2017

natureevents

ADVERTISEMENT